A 3-protein urinary panel risk score effectively stratified patients with idiopathic dilated cardiomyopathy, with the high-risk group exhibiting worse outcomes (HR 3.24; 95% CI 1.56-6.71; P=0.002).
Cohort (n=147)
Does a 3-protein urinary biomarker panel identify right ventricular dysfunction and predict adverse outcomes in patients with idiopathic dilated cardiomyopathy?
A novel 3-protein urinary biomarker panel accurately identifies right ventricular dysfunction and predicts adverse clinical outcomes in patients with idiopathic dilated cardiomyopathy.
Estimación del efecto: HR 3.24 (95% CI 1.56-6.71)
valor p: p=0.002
Background Right ventricular dysfunction (RVD) is a common complication of idiopathic dilated cardiomyopathy linked to poor outcomes. However, reliable noninvasive biomarkers for RVD remain lacking. This study aimed to identify urinary proteomic markers using mass spectrometry and machine learning. Methods In this prospective cohort, patients with idiopathic dilated cardiomyopathy were classified by cardiac magnetic resonance imaging into groups with RVD (RV ejection fraction <45%) and without RVD groups. Baseline urine samples were profiled by data‐independent acquisition mass spectrometry. Differentially expressed proteins were identified and selected by least absolute shrinkage and selection operator regression to build a diagnostic model, developed in a training set, and validated in a test set. The primary end point was a composite of cardiovascular death, heart failure rehospitalization, left ventricular assist device implantation, or heart transplantation. Results The study enrolled 147 patients with idiopathic dilated cardiomyopathy (64 with RVD, 83 without), with a median follow‐up of 19.3 months. Of 3579 quantified urinary proteins, 46 were differentially expressed between groups. A 3‐protein panel (RARRES1 retinoic acid receptor responder protein 1, MVB12B multivesicular body subunit 12B, GSK3A glycogen synthase kinase 3 alpha) was identified and showed excellent diagnostic accuracy (training area under the curve 0.946; validation area under the curve0.935), outperforming both NT‐proBNP (N‐terminal pro–brain natriuretic peptide) and tricuspid annular plane systolic excursion. The risk score derived from this panel effectively stratified patients, with the high‐risk group exhibiting significantly worse outcomes than the low‐risk group (hazard ratio, 3.24 95% CI, 1.56–6.71, P =0.002). Conclusions The urinary proteomic panel developed in this study demonstrates diagnostic and prognostic potential for identifying RVD in idiopathic dilated cardiomyopathy, providing a promising noninvasive tool for precise detection and clinical risk stratification.
Wu et al. (Wed,) conducted a cohort in idiopathic dilated cardiomyopathy (n=147). 3-protein urinary panel (RARRES1, MVB12B, GSK3A) vs. Low-risk group was evaluated on composite of cardiovascular death, heart failure rehospitalization, left ventricular assist device implantation, or heart transplantation (HR 3.24, 95% CI 1.56-6.71, p=0.002). A 3-protein urinary panel risk score effectively stratified patients with idiopathic dilated cardiomyopathy, with the high-risk group exhibiting worse outcomes (HR 3.24; 95% CI 1.56-6.71; P=0.002).